Insurance coding and insurance reimbursement is very important to the success and revenue generation of drugs and medical devices. It appears that it takes 18-24 months after FDA/EU approval to get them. Patients, Doctors, hospitals, clinics, etc. are slow to adopt and use drugs and devices until reimbursement is obtained. OPKO's serious revenue generation seems to be 2-3 years out at present. Will OPKO need to do another equity/stock offering before then?
I'm of the belief that the present management team in conjunction with the current financial groups supporting MELA over the past year have no intention of keeping MELA solvent in its present state. It is in their best interest over the next year or so, prior to insurance coding and reimbursement, to drive the stock price down and then take it out. It should then take 18-24 months to generate sales and revenues while in private hands. If my perception of Devices potential is correct they would then bring a company public between $100.-200 million. Not a bad return .........................
One doesn't need to be a weatherman to know which way the wind blows.
Does anybody know when OPKO filed for insurance reimbursement coding. It's my understanding it could take 18-24 months or longer from date of filing. If past experiences with new devices is any indicator, revenues from sales will be very small till Doctors, clinics, hospitals, etc. can pass on expense of machines and tests to patients and/or insurance companies. Has anybody seen any projections regarding revenue generation for 4kscore over the next year or so ?
If management would release a plan that showed revenue generation you might have a chance until then expect news of further dilution via an equity/stock offering.
Possibly Santa comes early and somebody/thing buys the patents..........................
I have been accumulating also. Would like to see some new contracts before I continue this is still a new and highly speculative company with a large short interest that will protect their position.
Today , prior to close, stock price gets driven down hard on blocks of 100 and rises slowly on blocks of 10,000. Short traders/ MM are shaking weak hands hard. One nice piece of good news and we see $.75-$1 in a New York minute. Small float, low priced stocks get played to much imo. Just part of the investing/speculating game.
WOW I didn't mean to create a threadline about managements ineptitude, my opinion has been documented in past posts; but rather a financial question regarding possible future dilution. My projection is if management is allowed to proceed, on current course, that it will need to raise capital prior to insurance reimbursement, if granted, and then again to finance sales resulting in a further devaluing stock price. The current value of the device, patents, etc. defies current valuation IMO.
Current values in the healthcare market place seem to dictate that MELA is, and will remain, in wall streets dog house for the foreseeable future. One can only blame management, past and current, for the situation. The current stockholders and Melanoma patients are the casualties. I think a deep pocketed healthcare activist, not the current financial engineers, is needed to rite MELA before all is lost. I agree with those who advocate actively holding management financially and legally responsible.
I have a few moments and I'm thinking about how many more equity/stock offerings [ further dilution ] Mela is going to do before being able to generate revenues being that insurance reimbursement is still almost 2 years out ?
IMO this top down approach by current management shows a total lack of imagination and money. First the technology should be available to the public in the form of a device that is sold at every drug store, on line retailer , etc. for something like $49.95 , they would sell millions worldwide. obviously a scaled down version used for periodical use and recommends seeing a Derm. if necessary. The Derms, hospitals, etc get the 3d top of line machine with all the benefits and advantages . The money generating ability of the technology and patents are staggering in the rite hands. I still believe this is being played by the money people and current stockholders are getting royally screwed .
could be early investors trading around their positions, taking profits, shaking out weak hands, and buying back at reduced profits. welcome to early stage, speculative investing.
will be like treading water for the stock price if management doesn't address the lack of revenue generation. Management needs to present a credible timeline showing revenue generation over the next year or two. Currently they have dropped the ball in this regard, it's hard putting a value on CGIX at the present time and without input this stock could go much lower, IMO. News/rumors/speculation could move the price greatly higher or lower at a moments notice, time for management to get proactive vs reactive.
numbers, how is QFOR not trading at over $1 ps at present ?
Ent. value $69m vs market value $59m
forward p/e 5.4
rev growth 31%+
l/f cash flow $2.5m
A first to market position in a multi billion $ market.
I believe CGIX is proceeding as they have projected from past calls and we are presently experiencing a shakeout of weak hands in the stock price. If clinical sales are as they state and will appear in the next quarter we might be experiencing a good buying opportunity during the next week or so.
Having heard the Analysts meeting and seen the quarters numbers, $4.2 cash/equv. on hand and $4.3 operating loss for quarter, I still have the same question for management. Where is the business plan? With revenue of $225k a quarter and no plan to grow that anytime soon, anybody care to venture what happens to present stockholders? Has anybody seen a business pro forma / plan ? Anything that has a timeline for revenue generation ? Any interest of buyout , partnering , sale , anything ?
All I'm seeing is the present financiers bleeding this company for the next year or so and taking it private just prior to Insurance reimbursement acceptance......................
The market will soon realize this is a real company with real earnings and a future. The market value will then reach and exceed the enterprise value which is 22%+ higher at the present time. With the last quarter in the books this gap should no longer exist IMO.